Efficacy of a new bronchodilator, Soterenol (cas 13642-52-9), on experimental locked-lung syndrome in dogs

Add time:09/08/2019    Source:sciencedirect.com

An experimental model resembling the “locked-lung syndrome” in humans has been produced in dogs, and the efficacy of soterenol, a new bronchodilator agent, has been studied. In a group of dogs in which isoproterenol was either ineffective or caused bronchoconstriction, soterenol, administered intravenously, intraduodenally, or given as an aerosol, effectively reduced bronchial airway resistance. A possible adverse action of isoproterenol on CO2 retention, which was corrected by soterenol, and other mechanisms which may be involved in producing a refractory state to isoproterenol have been discussed.

We also recommend Trading Suppliers and Manufacturers of Soterenol (cas 13642-52-9). Pls Click Website Link as below: cas 13642-52-9 suppliers

Prev:Electrochemical, fluorescence, and liquid chromatographic studies on the oxidation of Soterenol (cas 13642-52-9)
Next:Novel grafted electrochemical interface for covalent glucose oxidase immobilization using reactive PENTAFLUOROPHENYL METHACRYLATE (cas 13642-97-2))